3SOF

Lots of volume the last 2 days ,,2 and 3 x more normal.And yesterday....finished strong....and after the month of May,usually biotechs are weak.i will take a small position today..the "1.118 harmonic is $1.93..any lower then i will sell and be safe

The stock is on a downtrend. Can't buy stocks that are going down. But I wish you all the luck, I wish I buy this stock at a higher price when she's in an uptrend.

Thanks !

Thanks David for your feedback, :) I find it always good to get other traders views at times,on certain picks.

..one moment please,

you´re interested to make some money with a nice little healthcare stock? 

Then have a look to  VION PHARMACEUTICALS.  No debt, good pipeline and no financial problems. The chart offers a real good entry point if you want to make a fast double.



(http://ichart.finance.yahoo.com/z?s=VION&t=1y&q=b&l=on&z=m&p=&a=fs,ss,m26-12-9,r14)           

 
Recommendations from Nasdaq-Site   ;D



(http://screening.nasdaq.com/ibes/VION_cnb.jpg)



CIBC WORLD MARKETS CORP. 
LEERINK SWANN 
OPPENHEIMER & CO. 
RODMAN & RENSHAW, INC. 
WEDBUSH MORGAN SECURITIES INC. 
WELLS FARGO SECURITIES 
WESTPORT CAPITAL MARKETS, LLC

...told you the big POP is coming!


Take the chance  ;)

I agree small_invester...I picked some up at $2.19 on june15,,take a look at my post back on june 9 on here ;)..looking nice today at $2.55,gave you a point also :)

sorry Weightlifter, have missed your thread..



good luck

No worries,,,,Good Luck to us both 8)

Have a look to the  volume VION was traded on friday.

How many days in the last half year we have seen such an enormous volume?



http://stockcharts.com/def/servlet/SharpChartv05.ServletDriver?chart=vion,uu[w,a]daclyyay[pb50!b200][vc60][iub14!la12,26,9]&r=0907

..correction, the posted link to the chart chart doesn´t work as well...

sorry, but I don´t know why... ???

Hi !

VION on my filters tonight ;)

Love the chart:

Yep agree. This'll get to $3 in a hurry, nice move out of flag following trend break.

nice chart !

thanks to Ramsburg and [email protected] for the charts.  ;D

Volume is picking up a bit,,,I would like to see more then just 2 back -to back days of 1 million shares traded.though..The last time was in june04.and april04..biotechs were hot. I will post some harmonics next.

I am starting to like this play.  Picked it up on my radar today. May look to get in tomorrow.

VION....Nice move last few days no doubt.....However I dont see this stock going much above the $2.75 - $2.90 level on this break out......Look for the stock volume to dry up and a temp pullback in this area to consolidate......Lots of losers brought this stock down and lots of resistance going back........will watch and on pullback to the $2.40 - 2.50 level and (IF) buy volume starts coming in I might take a position........If stock runs off and leave me here I will find another, just that simple....Right?  Do your on DD though......and Happy trading!
Bill the Bull

K,,Here my thoughts on this,,going back to VION last November.high..i came up with these harmonics...stress points...=.886 harmonic..$2.39....the next is a Lucas harmonic which usually I find to be quite accurate,,=.854...$2.49...next is a fibo ..=.786..$2.71....next is a SS harmonic...707..$2.96...I see a double bottom,,2 low is higher then the first which is a postive,,,nice Candle,,,a modified Bull Hammer....TSF indicator is positive at the moment,so here what I think...i agree with gabillh that there could be a slight retracement,,but it you bought it at the bottom you are ahead on profits..i say if you want to buy then wait till it hits 2.39....then there is some extra room to work with .just my thoughts...Good Luck to anybody who is in.. :)

VION........Thats some heavy stuff there "weightlifter" pardon the pun.....LOL
Everything you are saying I agree with, however not everyone understands it all.....not even I, But the $2.39 is too precise.....I'll stick with a retest to the  $2.40 - $2.50 level....(You know we both may be wrong) so I still advise everyone to do the DD on their own....wouldnt want to have someone mad at me.....but in doing their own, they can keep this in mind..Roger?

happy trading     Bill the Bull

"Harmonics" are for lack of better terms,a expanded Fibonacci system.I find them better for several reasons.#1 At least for me,I find Fibo a little too limited and vague on expansions and break outs.when to sell.#2 They are different ratios at times from the normal fibo.,and at times I find them to be more accurate.#3 For me i dont like to use the 50 or 200 MA to confirm buys and sells.I rather use one of these,,especially if the current wave is say for example 10 days,i still will look at the MA but they do lag at times..#4 I use Harmonics for exact stops,,,At least for me I find that if put I in a stop its based on my own emotions and feelings,at times i will be a little too quick to sell.When I use a harmonic as a stop,All my subjective feelings are taken out of the evaluation process..I agree with you ,nothings perfect.Other wise I would have made my fortune by now and be sitting anywhere else instead of being in front of this computer lol ;) :D

Bought VION today at 2,55, thanks for this good pick, I like it. :-*

Think it will double in a few months, SP crossed above the weekly 10 SMA,
which is abullish sign I think.

Good luck for the longs.

therman

VION seems to make a nice jump today again. Look at the five day chart, isn´t it nice?
It´s one of the most promising charts I´ve seen in the last week.  ;D


Good luck to all longs

Some news about the Institutional Ownership in this stock:

Institutionals held now 58,35% in this stock,  last week there were 56% held by them.

Jay Goldman increased his stake by more than 840% from 133.000 shares to 1.259.000. :o


Think that´s real good news....


Good luck to the longs

small investor, chart looks real impressive. Good pick and pardon my ignorance, who is Jay Goldman? He is not one of the officers of the company.
I will probably buy today.
TIA
P

hello pete, something for you:

GOLDMAN JAY G 
152 W 57TH STREET 
NEW YORK, NY 10019 
212 262 4348 


He helds a portfolio with a total market value in the size of 378 Mio$.

Hi small investor,

can you give the link where you can see the institutional ownership?

Thanks.

therman

hi therman,

your wish is my command... ;)


http://www.nasdaq.com/asp/holdings.asp?mode=&kind=&symbol=vion&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&FormType=Institutional&mkttype=&pathname=&page=holdings&selected=VION

A very interesting situation seems to come next week. VION has made a little break in the last days but I expect it back to take the 3+ monday or tuesday.
Will go fishing for cheap shares at mondays first hour but not shure I can catch them with my limit...


We`ll see, good luck to longs

Hello again,

seems that someone has done the same like I : fishing  ;D
       
...fishing for cheap shares I mean!

Let´s have a look now to the chart. Think if we get over 2.90 today then....

...........let´s  r a l l y !!!!

SOME FUNDAMENTALS ABOUT INSTITUTIONAL OWNERSHIP


...have a look to the following numbers.
You can see some interesting facts about increased or decreased institutional ownership.

The "Top25" holders in VION held 29,54 Mio Shares.

> 12 increased Pos./ 6.362.532 Shares were bought in last actions

> 10 decreased Pos./ 4.177.701 Shares were sold in last actions

> 3 unchanged Pos./ no buying or selling action announced since 31/03/2005.


The real trend is they are accumulating Shares in a size 1,5x bought to sold shares. ;D

Think about!


good luck to longs

The volume is really light for a stock pushing out of the top band but still to watch as it may improve with BO at 2.90 but note the 200-day EMA overhead

(http://xs44.xs.to/pics/05353/vion3108.jpg)

Weightlifter, the stock did go up in price to around $3.00 when you
made the pick on 09  June. It has came dowm since then.
Way oversold. Indicators are turning north. Stochasticis coming out of oversold area.

Support @ $1.62
Resistance @ $1.79...1.92...2.02

Recent CandleStick Analysis
Very Bullish
Dec-30-2005 Bullish Engulfing 

Technicals
Last Price Quote is:
-2.93%below 13-day EMA
-13.66%below 50-day EMA
RS Rating: 7 

Fundamentals
Key Data:
Market Cap (M): $108.87 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 03/14/2006
Last Analyst Rating: Buy

Double bottom play!

In at 1.97 last week. Some big buys (100k) yesterday. Recently received orphan drug status for their drug  in clinical trials in the EU and fast track approval for certain indications in the US. Expecting FDA news by the end of the month.

Vion Pharmaceuticals Receives Orphan Drug Designation for Cloretazine(R) in Europe for Treatment of Acute Myeloid Leukemia

http://biz.yahoo.com/prnews/060123/nym040a.html?.v=1

(Just noticed 2 other threads on Vion already started after posting this, sorry)

News out

Vion Pharmaceuticals to Host Conference Call
Monday January 30, 4:15 pm ET

NEW HAVEN, Conn., Jan. 30 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. (Nasdaq: VION - News) will hold a conference call and simultaneous webcast on Tuesday, January 31, to provide an update on the clinical development of its lead anticancer agent Cloretazine®. The call will begin at 8:45 a.m. eastern time.

http://biz.yahoo.com/prnews/060130/nym216.html?.v=28

Should be interesting!

Vion Pharmaceuticals Announces Plans to Conduct a Pivotal Phase II Trial of Cloretazine(R) in Elderly Poor-Risk Acute Myelogenous Leukemia

http://biz.yahoo.com/prnews/060131/nytu033.html?.v=41

Up pre market last 2.10

Bid 2.10 Ask 2.65

VION makes me seasick just looking at the chart.(I am slightly green on this stock ;))

Huge volume yesterday, 600% increase 4 million shares traded.

Could be ready to make a move!

Vion has got news today...
It could rise today...
Low price now 1.55

[audio] Vion June 2006 Conference Call (recorded earlier today)


• Vion June 2006 Call scheduled for 8:45 am ET today
CCBN (Wed 8:45am) 
• InPlay: Vion Pharma provides update for clinical and preclinical programs
Briefing.com (Wed 7:09am) 
• Vion Pharmaceuticals Provides Update for Clinical and Preclinical Programs
PR Newswire (Wed 7:00am) 

today... we're @ 1.8 $

Applaud you Idfix...Look at the chart...

Hi Seb...watch !...your expectations were totaly correct! ;)


(http://C:%5CDocuments%20and%20Settings%5CRaymond%5CMes%20documents%5CMes%20images%5CSans%20titre.JPG)

Cheers,
Id...

 ;)


(http://\\assurancetourix\culture.la-gb1$\mes%20images\sans%20titre.jpg)

VION continues its run....1.78 yesterday... :)

Time to get in? I believe so... buy and hold :) :) :)


Cheers

Vion Pharmaceuticals to Present at Fortis Bank Biotechnology Conference
Monday April 23, 8:00 am ET


NEW HAVEN, Conn., April 23 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. (Nasdaq: VION - News) announced today that it would be making a corporate presentation at the 7th Annual Fortis Bank Biotechnology Conference on April 25, 2007. The conference is taking place at The Four Seasons Hotel, Park Lane in London, England.


The presentation will be at 9:45 a.m. EDT (2:45 p.m. British Summer Time (BST). The slides from the presentation will be posted to Vion's website, http://www.vionpharm.com, at 9:45 a.m. EDT on April 25, 2007.

Nice technical break-out today  :P

Cheers

Last Trade AH: $2.15

VION WAS AMONG THE TOP 5 NASDAQ LARGEST PERCENT GAINERS TODAY ON 5 TIMES THE AVERAGE TRADING VOLUME.

http://stockcharts.com/charts/gallery.html?vion (http://stockcharts.com/charts/gallery.html?vion)

TARGET: $$6+ BY YEAR END


VION's RECENT SIGNIFICANT DEVELOPMENTS (AND SOME OF THE CLUES FOR TODAY'S GAINS):

- APRIL 11, 2007. ANNOUNCEMENT OF THE HIRING OF AN INDUSTRY VETERAN TO LEAD VION's COMMERCIALIZATION EFFORTS (HINT: I beleve they anticipate FDA approval).

http://biz.yahoo.com/prnews/070411/nyw017.html?.v=93 (http://biz.yahoo.com/prnews/070411/nyw017.html?.v=93)

- APRIL 23, 2007. ANNOUNEMENT THAT VION WILL PRESENT AT FORTIS BIOTECHNOLOGY CONFERENCE ON APRIL 25, 2007.

http://biz.yahoo.com/prnews/070423/nym011.html?.v=83 (http://biz.yahoo.com/prnews/070423/nym011.html?.v=83)

- 4 ANALYSTS COVERING THE STOCK CURRENTLY HAVE AN AVERAGE PRICE TARGET OF $4.5

http://finance.yahoo.com/q/ao?s=VION (http://finance.yahoo.com/q/ao?s=VION)

- VION's MARKET CAP IS ONLY $145M

- VION HAS $31 IN CASH AND NO LONG-TERM DEBT

http://finance.yahoo.com/q/bs?s=VION&annual (http://finance.yahoo.com/q/bs?s=VION&annual)

- HEAVY INSIDER BUYING

http://finance.yahoo.com/q/it?s=VION (http://finance.yahoo.com/q/it?s=VION)


The April 11, 2007 announcement of the hiring of Dr. James Tanguay, Ph.D. as the Company's senior management team as Vice President, Chemistry, Manufacturing & Control, and heavy recent insider buying suggest that VION is anticipating that the FDA will approve its  Cloretazine® (VNP40101M) drug candidate which is in late-stage clinical trials for the treatment of acute myelogenous leukemia.

The key paragraphs of that announcement follow:

Dr. Tanguay was formerly Vice President, Technical Operations at Kos Pharmaceuticals, acquired by Abbott Laboratories in 2006 for $3.7 billion. From 2003 until recently, he was responsible for strategic planning and administration of all domestic and international commercial manufacturing, testing and distribution. In 2005, Kos Pharmaceuticals reported net sales of over $725 million from multiple products.

Alan Kessman, Chief Executive Officer said, "We are extremely pleased to have Jim Tanguay joining Vion to lead our manufacturing operations. His experience helping build Kos Pharmaceuticals through the initial commercialization of its products, and until its eventual sale to Abbott Laboratories, will be directly applicable to what we are trying to accomplish at Vion."

Dr. Tanguay commented, "I am excited to be joining a company which has a novel cytotoxic agent like Cloretazine® (VNP40101M) in late-stage clinical trials for the treatment of acute myelogenous leukemia. Furthermore, Vion has a number of other interesting anticancer products in various stages of development." He concluded, "I look forward to working with the whole team at Vion to bring new anticancer products to market with the goal of improving the treatment of cancer patients worldwide."


About VION:

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine® (VNP40101M), a unique alkylating agent, is being evaluated in: (i) a Phase III trial in combination with cytarabine in relapsed acute myelogenous leukemia and (ii) a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. An additional trial of Cloretazine® (VNP40101M) as a single agent in small cell lung cancer is also underway. Triapine®, a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET®, its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com (http://www.vionpharm.com).[/QUOTE]

In case you haven't seen it, there is an existing VION topic right underneath yours.  ::)

Sweet PM activity  :)


Cheers

"VION" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.    ;D                                             
All history on a stock pick in 1 thread is awesome.   ;)                                           
Just trying to get threads together,so we don't have a numerous amount floating around on the same stock.   :( ::)                               
Thank You....and good luck with all your trades....make some $$$     ;)       

Indeed it is much easier when doing research. 

Thank you, set :)


Cheers

VION is a buy and hold, but you want to trade the stock I'd suggest you keep a core position in it.

Cheers

Stock-kitty

I agree with you 100%. I am not selling one share until VION gets FDA approval for Clorezantine to cure Leukemia. Response rates at high as 50% are unheard of. THe FDA hass approved many drugs for leukemia with that response rate. Furthermore, Clorezantine has an excellent safety profile. VION in a few months will be a double-digit stock IMO.

Lots of talk about VION's volume and price action today. Some believe that some results of VION's Phase 2 small-cell lung cancer trials be presented in June1 at the ASCO annual meeting might have leaked. Apparently this has been happening lately and it is affecting the stocks involved positively and negatively.

http://www.thestreet.com/_yahoo/newsanalysis/biotech/10357592.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA


It is very possible that the results of Cloretazine are indeed positive and consistent with Phase I results in terms of safety and effectiveness.

Her is one of the commentaries on today's surprising rally:

http://biohealthinvestor.com/2007/05/biowatch-alert-vion-jumps-on-strong.html

Vion Crushed After Study Halted

Vion Pharmaceuticals (VION - Cramer's Take - Stockpickr - Rating) plummeted 56% Wednesday morning after it announced that a late-stage trial for the leukemia drug Cloretazine has been suspended.
The company halted enrollment and further treatment in the Phase III trial of Cloretazine, which is used for patients with relapsed adult myelogenous leukemia, on the recommendation of the study's Data Safety Monitoring Board.

After an interim analysis, the board felt the advantage of the treatment could be compromised by the mortality rate observed in the study.

"There will be a thorough analysis of all the data to date from this trial, and we will base any decision on the continuation, possible modification or termination of the study on the available data," said Chief Executive Alan Kessman.

Vion's shares plunged $1.10, to 91 cents, in premarket trading.

OUCH!!!!!

This came very unexpectedly but that is the risk with biotech companies... :(

Yes indeed. But like i said before. I am a long-term VION investor. This is a temporary setback as the CEO said yesterday. Furthermore, VION made the decision to Halt Phase 3 upon further review of the data. ...it was not mandated by the FDA. And it was not stopped either.

I expect a bounce going into ASCO.

That's how I view it too, as a temporary setback. There is still the phase II (also for AML) and of course the day VION announces the restart of the phase III trial with renewed data, the PPS should move back up to where it was before the crash.
The fact that they have double checked should give investors even more confidance that the company has made the right decision at this point in time and that they have acted with the best interest.


Cheers

VION management did the right thing by announcing the Phase III halt before ASCO. Otherwise,  VION would steam roll heading into the conference (because there are already indications that the data they will present will be excellent) and it would lilely explode clear into the $3+ area. Had the company dropped the bomb after ASCO, they would be hit with many lawsuits and be considered as pumper/dumpers etc.

Since VION is now so oversold, has $1/share cash, a significant cancer drug pipeline (not including the halted program), and is about to present great data on 2 clinical studies at ASCO, I expect a 50 - 70% bounce within 2 weeks.

I also believe that VION, upon careful review, will be given the green light to resume the Phase II programs...maybe with some changes here and there. VION management believes  Cloretazine by itself has an excellent long-term safety profile, and that's what I've herd through friends that work at M. D. Anderson hospital in Houston.

Right now trading is being controlled by hedge funds and skillful MMs.  After they accomplished their objectives (steal shares from impatient and fearful retail investors) they will be the catalyst for the inevitable bounce.

BTW, there was a trade of 1.6M shares AH yesterday.

Cheeers!

HEADS UP...THIS COULD BE SIGNIFICANT FOR VION....

NOTE: THESE CLINICAL RESULTS WILL BE PUBLISHED IN JUNE, 2007...THIS IS UNRELATED TO VION's 2 ASCO PRESENTATIONS NEXT WEEK.

Cancer Chemotherapy and Pharmacology-. 2007 Jun;60(1):45-51.

Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models.

* Zheng LM,
* Li Z,
* Liu L,
* Song BL,
* King I.

Vion Pharmaceutical, Inc., 4 Science Park, New Haven, CT, 06511, USA, [email protected].

Cloretazine (VNP40101M), a new sulfonylhydrazine alkylating agent, has demonstrated broad-spectrum anti-tumor activity in preclinical studies.

In this study, Cloretazine was evaluated both as a monotherapy and in combination with fludarabine in murine tumor and human tumor xenograft models. Cloretazine significantly inhibited the growth of subcutaneously implanted tumors, including B16F10 murine melanoma in C57BL/6 mice, and H460 human lung carcinoma and WiDr human colon carcinoma in athymic nude CD1 mice.

The inhibition of tumor growth by Cloretazine was dose dependent, increasing from 42.2 to 87% as the dose escalated from 100 to 150 mg/kg. Cloretazine showed equivalent efficacy but lower toxicity compared to cyclophosphamide (Cytoxan) in these models.

The combination therapy, consisting of a single dose of 10 mg/kg Cloretazine plus five doses of 70 mg/kg fludarabine, given every other day intraperitoneally, significantly increased the long-term survival of BDF1 mice bearing the L1210 murine leukemia.

On Day 65 post-tumor implantation, the combination therapy yielded a 90% survival rate compared to 40% for Cloretazine alone and 0% for fludarabine alone.

Read again..."90% survival rate"....and ..."equivalent efficacy but lower toxicity compared to cyclophosphamide (Cytoxan) in these models."

Here is the link:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17256135&query_hl=5&itool=pubmed_docsum

I believe that these developments are even more significant than the ASCO results that will be published next week.

This study says that VION's Cloretazine is very effective in inhibiting the growth of several types of tumors ...with an excellent safety profile....if fact the study concludes that Cloretazine is more effective and less toxic than Citoxan which sells in the $$billions/year!!!

VION may rock and roll this week. The following is the abstract of the main paper to be presented by VION at the ASCO meeting. Should have a bullish PR is the morning.


phase II trial of VNP40101M in patients with relapsed or refractory small cell lung cancer (SCLC) with or without brain metastases.

Sub-category:
   
Small Cell Lung Cancer

Category: Lung Cancer

Meeting: 2007 ASCO Annual Meeting
   
   
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 7724
Author(s):
   
T. Mekhail, S. Gettinger, G. Blumenschein, R. Axelrod, M. Haigentz, M. J. Guarino, A. L. Cahill, D. Spigel, F. A. Greco
Abstract:
   
Background: Relapsed or refractory SCLC patients (pts) have a poor prognosis. Median survival at relapse is 2-3 months; brain metastases (mets) are common. Alkylating agents have demonstrated activity in SCLC. Cloretazine is a new alkylator that is active against selected alkylating agent resistant tumor cell lines. Xenograft models show distribution across the blood-brain barrier. This study investigates VNP40101M safety and activity in SCLC patients who have relapsed or are refractory to standard 1st line chemotherapy. Methods: Pts are entered in 2 groups based on response to prior chemotherapy: sensitive relapse (chemotherapy-free interval >3 months); or resistant/refractory (chemotherapy-free interval <3 months). Eligibility criteria include: measurable or evaluable disease; life expectancy of >2 months; and ECOG PS of 0-2. Pts with brain mets are eligible. 31 pts received VNP40101M IV at a starting dose of 125 mg/m2/wk × 3, every 6 weeks. Due to a high incidence of grade 3-4 thrombocytopenia (34%), an amended protocol reduced the dose of VNP40101M to 100 mg/m2 at the same schedule. 13 pts received the reduced dose. Pts are evaluated by RECIST criteria after each 6-week cycle. Results: 44 of 87 planned pts have been treated at 7 sites. Of 41 evaluable pts, 21 patients have sensitive relapse disease, and 20 have resistant/refractory disease. Median age is 64 years (44-86). Median number of cycles received is 1 (1-3). Grade 3-4 thrombocytopenia was seen in 11/31 pts at the 125 mg/m2 dose and 3/13 pts at the 100 mg/m2 dose. Gr 3-4 non-hematologic toxicity is rare, except for fatigue (10%) and GI effects (10%).

The response rate (PR) is 6/21 (29%) in the sensitive relapse group, and 1/20 (5%) in the resistant/refractory group. 2/6 PRs, in the sensitive relapse group, occurred at the reduced dose level. 16 pts had brain mets at study entry. Of these, there were 3 PRs (2 with measurable regression of brain mets) and 3 stable diseases.

Conclusions: The study is ongoing to confirm efficacy and safety. VNP40101M has activity against SCLC in the 2nd line setting including pts with brain metastases; further study is warranted.

KEYS: RESPONSE RATE OF 29% IN ONE GROUP/STUDY CONFIRMS EFFICACY AND SAFETY

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=47&abstractID=33847

VION PRESENTS EXCITING RESULTS AT ASCO.......

VION'S CLOREZATINE PHASE II SMALL CELL LUNG CANCER TRIALS SHOW EXCELLENT RESULTS......A SECOND PAPER USING CLOREZATINE FOR PEDIATRIC BRAIN TUMORS WILL BE PRESENTED THIS AFTERNOON..

REGARDING PHASE II SMALL CELL LUNG CANCER TRIALS:

Dr. F. Anthony Greco, Director of the Sarah Cannon Research Institute in Nashville, Tennessee, commented, "Cloretazine® (VNP40101M) has impressive activity in small cell lung cancer in the second-line setting, including activity against brain metastases, and further evaluation is warranted."

Ann Cahill, Vion's Vice President, Clinical Development, said, "Our solid tumor clinical development plan for Cloretazine® (VNP40101M), which includes our Phase II trial in small cell lung cancer, and the recently completed trials in adult and pediatric brain tumors, is an important part of the overall clinical development program for this novel alkylating agent." Ms. Cahill added, "We are encouraged by this promising data in small cell lung cancer."

INTRO ON THIS AFTERNOON'S VION PRESENTATION:

Additional data from a Phase I trial conducted by the Pediatric Brain Tumor Consortium of Cloretazine® (VNP40101M) as a single agent in pediatric brain tumors will be presented at the ASCO Annual Meeting in poster U1 in S Hall A2 at the McCormick Place Convention Center on Monday, June 4, 2007 from 1 to 5 p.m.

http://biz.yahoo.com/prnews/070604/nym064.html?.v=74

Recent data, yet to be published,  shows remarkable Clorezatine activity in many types of cancer:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17256135&query_hl=5&itool=pubmed_docsum

http://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=17522334

VION has lots of potential. During last weeks CC they mentioned an NDA filing for a ph2 trial which they are working on and that they are looking for a partnership.
If any of these catalysts will be announced (and my guess is within a couple of weeks) then this stock will be over $1.